SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001599298-23-000015
Filing Date
2023-01-27
Accepted
2023-01-27 16:05:51
Documents
13
Period of Report
2023-01-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20230127.htm   iXBRL 8-K 38643
  Complete submission text file 0001599298-23-000015.txt   205235

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20230127.xsd EX-101.SCH 2159
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20230127_def.xml EX-101.DEF 14830
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20230127_lab.xml EX-101.LAB 28736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20230127_pre.xml EX-101.PRE 15427
7 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20230127_htm.xml XML 11114
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 23562763
SIC: 2834 Pharmaceutical Preparations